Pan European patient organisation funding

The European Federation of Allergy and Airways Diseases Patients Associations (EFA)

EFA is a European network of allergy, asthma and COPD patient organisations that was founded in 1991, prompted by the belief that an international organisation formed by European patients associations that share the same aims would be a more effective way to serve the needs and safeguard the rights of patients and their carers.

We have supported this organisation since 1997.

During 2020:

GSK provided:

- 30,000 euro in support of corporate partnership, which involved EFA’s first online Annual General Meeting of Members (AGM) and 18 calls with the EFA working groups, which helped coordinate World Disease Days and the EFA Allergy and Respiratory Patients’ Conference and to define the EFA strategy 2021-2027.
- 10,000 euro for capacity building which involved
  - Allergy and Respiratory Patients Digital Conference where several speakers, experts in digitalisation in the healthcare sector, presented and engaged with the public. The aim of this day was to provide patients with trainings, aiming at increasing their digital skills and their confidence in a digital environment.
  - Meet and Greet the EU event to increase understanding among EFA patient networks about the policies and opportunities.
  - Targeted training for EFA members
- 25,000 euro for Show Leadership project that involved:
  - Adoption of Breathe Vision for 2030, a document that outlines the changes that lung patients want to see in their lives in the coming decade in the areas of Awareness, Prevention, Access, Research, and the Impact of COVID-19, all while working towards a European Health Union.
  - Adoption of a revised Interest Group strategy 2020-2024. The strategy is based on a vision to engage EU policymakers and stakeholders to trigger evidence-based policy change on allergy and asthma.
  - Launch of the Allergy & Asthma Youth Parliament to establish a platform for the next generation of health leaders. Their role is to inform European policymakers on how their work can support young people living with asthma and allergies.
- 3305 euro for attendance at GSK’s Patient Advocacy & Advisory Board (PAAB)

Our support represents 8.44% of their overall income.

During 2019:

- We provided €30,000 core membership to support the group in delivering its objectives.
• We provided €30,000 for the Patient Challenge project to raise the profile of allergy, asthma and COPD in the EU and the needs of patients suffering from them.
• We provided €20,000 for capacity building and enabling EFA and its members to exchange knowledge and contribute to EU and international level campaigns.
• We provided €1,365 for attendance at GSK’s Patient Advocacy Advisory Board (PAAB). We also provided travel and accommodation for this meeting.
• We provided €1,200 for attendance at GSK’s European Health Advisory Board (HAB). We also provided travel and accommodation for this meeting.

Our support represented 9.3% of their overall income.

During 2018:
• We provided €30,000 core membership to support the group in delivering its objectives.
• We provided €40,000 for Active Patient Access Survey in seven European countries, on asthma and COPD diagnosis and treatment.
• We provided €30,000 for Severe Asthma Awareness campaign.
• We provided €1,200 for attendance at GSK’s Patient Advocacy Advisory Board (PAAB).
• We provided €600 for attendance at GSK’s European Health Advisory Board (HAB). We also provided travel and accommodation for this meeting.

Our support represents 8.75% of their overall income.

During 2017:
• We provided an unrestricted grant of €30,000 to support the group in delivering its objectives.
• We also provided €40,000 to support EFA’s COPD Move project consisting of patient videos aimed at raising awareness about the benefit that active COPD patients have and motivate other patients.

Our support represents 7.6% of their overall income.